2020
132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects
INZUCCHI S, KRAUS B, WEIR M, BAKRIS G, MATTHEUS M, CHERNEY D, SATTAR N, HEERSPINK H, RITTER I, EYNATTEN M, ZINMAN B, WANNER C, KOITKA-WEBER A. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. Diabetes 2020, 69 DOI: 10.2337/db20-132-lb.Peer-Reviewed Original ResearchBoehringer Ingelheim-LillyCV deathBoehringer Ingelheim PharmaceuticalsMundipharma InternationalBaseline characteristicsNovo Nordisk A/SJanssen PharmaceuticalsEli LillyRisk reductionEMPA-REG OUTCOMEKDIGO risk categoriesPredictive baseline factorsRenal hemodynamic effectsSerious adverse eventsAdvanced kidney diseaseAdvisory PanelGlomerular filtration rateJanssen Scientific AffairsMultivariate logistic regressionDeath risk reductionNovo NordiskDiuretic therapyEGFR declineSanofi GenzymeCV disease271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF
INZUCCHI S, DOCHERTY K, KOBER L, KOSIBOROD M, MARTINEZ F, PONIKOWSKI P, SABATINE M, SOLOMON S, BELOHLAVEK J, BÖHM M, CHIANG C, DE BOER R, DIEZ M, DUKAT A, LJUNGMAN C, VERMA S, DEMETS D, BENGTSSON O, LANGKILDE A, SJÖSTRAND M, JHUND P, MCMURRAY J. 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF. Diabetes 2020, 69 DOI: 10.2337/db20-271-or.Peer-Reviewed Original ResearchNovartis Pharmaceuticals CorporationBoehringer Ingelheim PharmaceuticalsBristol-Myers SquibbIncidence of diabetesNovo Nordisk A/SHeart failureJanssen PharmaceuticalsNovartis AGDAPA-HFEisai Inc.Incident T2DSpeakers bureauEli LillyGlaxoSmithKline plcCox proportional hazards modelDaiichi SankyoBenefit of dapagliflozinNew-onset T2DPrespecified exploratory analysisSGLT2 inhibitor dapagliflozinNew-onset diabetesAdvisory PanelEffect of dapagliflozinPfizer Inc.Janssen Scientific Affairs28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME
VERMA S, LEITER L, SHARMA A, ZINMAN B, MATTHEUS M, FITCHETT D, GEORGE J, OFSTAD A, WANNER C, INZUCCHI S. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-28-or.Peer-Reviewed Original ResearchCV deathEMPA-REG OUTCOMEAtherosclerotic cardiovascular diseaseHazard ratioNovo Nordisk A/SJanssen PharmaceuticalsBristol-Myers SquibbTreatment initiationEli LillyEMPA-REG OUTCOME trialCox proportional hazards modelAdvisory PanelBenefits of empagliflozinRisk of HHFRisk of hospitalizationNumber of patientsType 2 diabetesProportional hazards modelCumulative incidence curvesNovartis Pharmaceuticals CorporationPost Hoc AnalysisBayer AGBoehringer Ingelheim PharmaceuticalsEmpagliflozin 10Empagliflozin doses927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4
PRATLEY R, BAUER R, INZUCCHI S, KHUNTI K, KREINER E, LAURSEN P, MEIER J. 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4. Diabetes 2020, 69 DOI: 10.2337/db20-927-p.Peer-Reviewed Original ResearchNovo Nordisk A/SDohme Corp.Oral semaglutideMerck SharpGLP-1RAsSanofi-AventisNovartis AGRoche PharmaSGLT2 inhibitorsSubgroup analysisEli LillyGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsDaily oral semaglutideTrial product estimandGastrointestinal adverse eventsLexicon PharmaceuticalsSubgroup of patientsJanssen Scientific AffairsType 2 diabetesBayer AGBoehringer Ingelheim PharmaceuticalsAdvisory PanelSubcutaneous liraglutideT2D duration
2019
159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.Peer-Reviewed Original ResearchEMPA-REG OUTCOMEAdverse eventsBoehringer Ingelheim PharmaceuticalsPlasma glucoseMyocardial infarctionCause deathCV outcomesJanssen PharmaceuticalsType 2 diabetes mellitusEli LillyRisk of MIHeart failure hospitalizationRisk of HHFCardio-protective effectsCox regression modelAdvisory PanelCV deathCV diseaseFailure hospitalizationPlacebo groupDiabetes mellitusDohme Corp.Novo Nordisk A/STime-varying covariatesMerck Sharp19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME
INZUCCHI S, KHUNTI K, FITCHETT D, WANNER C, MATTHEUS M, GEORGE J, PERNILLE OFSTAD A, ZINMAN B. 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-19-lb.Peer-Reviewed Original ResearchRisk factor goalsCV deathDohme Corp.Boehringer Ingelheim PharmaceuticalsNovo Nordisk A/SJanssen PharmaceuticalsMerck SharpTakeda Pharmaceutical Company LimitedHazard ratioRisk factorsNovartis AGEli LillyACE inhibitor/ARB useCV risk factor controlConsistent cardiovascular benefitEMPA-REG OUTCOMECV risk factorsRisk factor controlPfizer Inc.Sanofi-AventisNon-smoking statusAdvisory PanelPost Hoc AnalysisCV risk increasesARB use248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
INZUCCHI S, ZINMAN B, GEORGE J, MATTHEUS M, EYNATTEN M, WANNER C, HAUSKE S. 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial. Diabetes 2019, 68 DOI: 10.2337/db19-248-or.Peer-Reviewed Original ResearchNon-proteinuric chronic kidney diseaseEffect of empagliflozinChronic kidney diseaseCardiorenal outcomesBoehringer Ingelheim PharmaceuticalsEMPA-REGCV deathKidney diseaseJanssen PharmaceuticalsEli LillyAdverse cardiorenal outcomesComposite kidney outcomeLower proteinuria levelsPrior CV diseaseSubgroup of patientsStrong risk predictorType 2 diabetesAdvisory PanelCKD populationKidney outcomesOvert albuminuriaOvert proteinuriaCause mortalityCV diseaseLower eGFR
2018
What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial?
INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.Peer-Reviewed Original ResearchTransient ischemic attackDensity lipoprotein cholesterolInsulin resistanceCV benefitsLog HRCardiovascular benefitsLipoprotein cholesterolBlood pressureStroke/transient ischemic attackHigh-sensitivity C-reactive proteinHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolMeasures of IRInsulin Resistance InterventionHomeostatic model assessmentDiastolic blood pressureEffect of pioglitazoneSystolic blood pressureC-reactive proteinFavorable effectBoehringer Ingelheim PharmaceuticalsPIO effectIschemic attackNondiabetic patientsHOMA-IREmpagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline
FITCHETT D, SCIRICA B, INZUCCHI S, CANNON C, MCGUIRE D, JOHANSEN O, SAMBEVSKI S, HEHNKE U, GEORGE J, ZINMAN B. Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline. Diabetes 2018, 67 DOI: 10.2337/db18-1123-p.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialBoehringer Ingelheim PharmaceuticalsBaseline CV riskCV deathProportion of patientsCause deathEisai Inc.CV riskOutcome trialsRisk scoreJanssen PharmaceuticalsGlaxoSmithKline plcBristol-Myers Squibb CompanyNovo Nordisk A/SLexicon PharmaceuticalsEli LillyBenefits of empagliflozinBoehringer Ingelheim GmbHResidual CV riskEffect of empagliflozinTIMI risk scorePfizer Inc.Sanofi-AventisCardiovascular risk scoreAmgen Inc.Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry
WONG N, SONG Y, ARNOLD S, SPERLING L, CANNON C, INZUCCHI S, KOSIBOROD M. Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry. Diabetes 2018, 67 DOI: 10.2337/db18-1487-p.Peer-Reviewed Original ResearchDiabetes Collaborative RegistryDiabetes mellitusBoehringer Ingelheim PharmaceuticalsJanssen PharmaceuticalsBristol-Myers Squibb CompanyCollaborative RegistryGlaxoSmithKline plcHigh-intensity statin usePfizer IncU.S. adultsBoehringer Ingelheim GmbHLow ASCVD riskRisk factor targetsAmgen Inc.Multiple logistic regressionAmgen IncASCVD preventionEisai Inc.ASCVD riskStatin useBlood pressureDM medicationsMultifactorial interventionMale sexNovo Nordisk A/SRelationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort
RASOULI N, COHEN R, DEFRONZO R, INZUCCHI S, ISMAIL-BEIGI F, KAHN S, UTZSCHNEIDER K, LACHIN J, YOUNES N. Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort. Diabetes 2018, 67 DOI: 10.2337/db18-1822-p.Peer-Reviewed Original ResearchC-peptide responseBaseline phenotypic characteristicsDisposition indexInsulin sensitivityBoehringer Ingelheim PharmaceuticalsΒ-cell functionT2D durationJanssen PharmaceuticalsBristol-Myers Squibb CompanyNational Diabetes Education ProgramBoehringer Ingelheim GmbHBeta-cell responseType 2 diabetesΒ-cell responseDiabetes education programΒ-cell dysfunctionWaist circumferenceBlood InstituteKidney diseaseNational HeartAbbVie Inc.Grade cohortsCelgene CorporationDisease controlBaseline phenotypeEmpagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c
WANNER C, COOPER M, INZUCCHI S, ZINMAN B, HEHNKE U, EYNATTEN M, KOITKA-WEBER A. Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c. Diabetes 2018, 67 DOI: 10.2337/db18-524-p.Peer-Reviewed Original ResearchControl of BPLow-density lipoprotein cholesterolRisk of incidentCV risk factorsBlood pressureBoehringer Ingelheim PharmaceuticalsRenal outcomesLipoprotein cholesterolRisk factorsJanssen PharmaceuticalsConventional CV risk factorsEMPA-REG OUTCOME trialBoehringer Ingelheim GmbHDiastolic blood pressureSystolic blood pressureEli LillyAbbVie IncEMPA groupSanofi GenzymeHazard ratioInhibitor empagliflozinRenoprotective roleTime-dependent covariatesOutcome trialsDohme Corp.